このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Telerehabilitation and Biomarkers of Recovery After Stroke in Brazil (TR-BR-1)

2026年6月9日 更新者:Taiza G. S. Edwards, PhD、University of Sao Paulo

Telerehabilitation and Biomarkers of Functional Recovery After Stroke in Brazil: TR-BR-1 Clinical Trial

The purpose of this research study is to provide preliminary evidence of whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone in Brazil. Evaluate the safety and feasibility of telerehabilitation in the Brazilian context. Explore the clinical, neuroimaging, neurophysiological, and economic factors that influence telerehabilitation efficacy in functional recovery following stroke.

調査の概要

状態

まだ募集していません

条件

詳細な説明

This is a two-arm phase II randomized controlled trial with blinded outcome assessment. A total of 20 post-stroke participants will be randomized to either telerehabilitation added to usual care (TR+UC) or usual care alone (UC). The primary outcome measure is the Action Research Arm Test (ARAT), which assesses upper extremity motor function. Secondary measures will include feasibility and intervention-related outcomes.

Study participation will span approximately 4 months and includes 6 in-person assessment visits. At these visits, participants will complete a battery of assessments, including upper extremity motor function tests, resting-state functional electroencephalography (EEG), and a single magnetic resonance imaging (MRI) scan of the brain. Participants assigned to the TR+UC group will receive structured arm motor training consisting of 36 sessions of prescribed exercises, interactive games, and stroke education delivered over 6 weeks at a frequency of 6 days per week, with each session lasting approximately 70 minutes. TR+UC participants will continue all usual care concurrently. Participants in the UC group will continue all therapies recommended by their medical team without participating in telerehabilitation.

研究の種類

介入

入学 (推定)

20

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Taiza G. S. Edwards, PhD
  • 電話番号:+5516-36021202
  • メールtrbr1@usp.br

研究連絡先のバックアップ

  • 名前:Antonio Carlos Santos, MD, PhD
  • 電話番号:+551636022964

研究場所

    • São Paulo
      • Ribeirão Preto、São Paulo、ブラジル、14049900
        • Ribeirão Preto Medical School, University of São Paulo
        • コンタクト:
          • Taiza G. S. Edwards, PhD
          • 電話番号:+5516-36021202
          • メールtrbr1@usp.br
        • コンタクト:
          • Antonio Carlos dos Santos, MD, PhD
        • 主任研究者:
          • Taiza G. S. Edwards, PhD
        • 副調査官:
          • Antonio Carlos dos Santos, MD, PhD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  1. Age 18-80 years at the time of randomization.
  2. The index stroke was radiologically verified, due to ischemia, and had time of onset 120±30 days prior to randomization.
  3. The stroke caused upper extremity deficits as defined by Action Research.
  4. Arm Test score 18-44 (out of 57) at Baseline Visit.
  5. Box & Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit.
  6. Able to successfully perform all 3 rehabilitation exercise test examples (simple commands) at Baseline Visit.
  7. Informed consent and behavioral contract signed by the subject (i.e., no surrogate consent).

Exclusion Criteria:

  1. A major, active, coexistent neurological, psychiatric, or medical disease that reduces the likelihood that a subject will be able to comply with all study procedures.
  2. Unable or unwilling to perform study procedures/therapy, or expectation of noncompliance with study procedures/therapy, or expectation that subject cannot participate in all study visits.
  3. A diagnosis (apart from the index stroke) that substantially affects paretic arm function.
  4. Severe depression, defined as Geriatric Depression Scale Score >10/15 at Baseline Visit.
  5. Significant cognitive impairment, defined as Montreal Cognitive Assessment [a lower score can be permitted at the discretion of the PI].
  6. Deficits in communication that interfere with reasonable study participation.
  7. Severe UE spasticity, defined as presence of contracture or modified Ashworth Scale score=4 in either biceps or pectoralis.
  8. Modified Rankin Scale score >2 prior to the index stroke.
  9. A new symptomatic stroke has occurred since the index stroke, or a separate stroke occurred within 30 days prior to the index stroke.
  10. Lacking visual acuity, with or without corrective lens, of 20/50 or better in at least one eye.
  11. Life expectancy < 9 months
  12. Pregnancy; women of child-bearing potential must have a negative pregnancy test.
  13. Botulinum toxin to the paretic arm: received in the prior 3 months or expected by the 1-Month Visit.
  14. Concurrent enrollment in another therapy-based investigational study where the duration of the investigational therapy's activity is likely to occur during the subject's participation in the study.
  15. Subject lacks sufficient Portuguese to comply with study procedures and TR instructions.
  16. Contraindication to MRI.
  17. Contraindication to TMS.
  18. Box and Block Test score of ≥30 blocks with the unaffected arm within 60 seconds at Baseline Visit;
  19. Spatial neglect interfering with reasonable participation in the study;
  20. On isolation precautions, e.g., due to active COVID-19.
  21. Expectation that participant will not have a single domicile address during the 6 weeks of therapy.
  22. Distance from the participant's home to the study site greater than 120 km [this can be waived at the discretion of the PI].

22. Availability of a 2 m² space for a table and chair setup.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
他の:Usual Care
Participants in the usual care group will receive no TR, but will continue with the recommendations made by their care team.
Usual care rehabilitation refers to the recommendations made by their care team.
アクティブコンパレータ:Telerehabilitation + Usual Care
In addition to the usual care, patients will receive 36 telerehabilitation sessions targeting arm motor function in addition to their usual care. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently.
Usual care rehabilitation refers to the recommendations made by their care team.
Participants will receive 36 telerehabilitation sessions targeting arm motor function in addition to their usual care. TR consists of 70 minutes/day of activities targeting arm function, 6 days/week for 6 weeks. Half of these sessions are supervised by a licensed therapist, and the other half are done independently.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Action Research Arm Test (ARAT) Score from baseline to the early post-intervention.
時間枠:From baseline to early (within 7 days) post-intervention
Change in Action Research Arm Test (ARAT) Score from baseline to the early post-intervention. The ARAT scale measures arm function using a scale that runs from 0 to 57 points, with higher numbers reflecting better arm function.
From baseline to early (within 7 days) post-intervention
Study feasibility in the Brazilian context - recruitment.
時間枠:Through recruitment completion - an average of 15 months
Proportion of eligible participants who agree to take part in the study.
Through recruitment completion - an average of 15 months
Study feasibility in the Brazilian context - adherence.
時間枠:Through study completion (specifically end of therapy) - an average of 17 months
Proportion of participants who complete TR therapy with sessions of 40 minutes or longer.
Through study completion (specifically end of therapy) - an average of 17 months
Study feasibility in the Brazilian context - retention.
時間枠:Through study completion (specifically end of follow-up) - an average of 18 months
Proportion of dropouts during the study participation period.
Through study completion (specifically end of follow-up) - an average of 18 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Action Research Arm Test (ARAT) Score from baseline to 1 month post-intervention.
時間枠:From baseline to 1 month post-intervention
Change in Action Research Arm Test (ARAT) Score from baseline to 1 month post-intervention. The ARAT scale measures arm function using a scale that runs from 0 to 57 points, with higher numbers reflecting better arm function.
From baseline to 1 month post-intervention
Treatment-related adverse events reported by the participants.
時間枠:From the start of TR to early (within 7 days) post-intervention
Number and severity of adverse events related to the telerehabilitation intervention reported by the participants.
From the start of TR to early (within 7 days) post-intervention

その他の成果指標

結果測定
メジャーの説明
時間枠
White matter integrity assessed using diffusion tensor imaging (DTI) magnetic resonance imaging (MRI).
時間枠:Baseline
Cortical spinal tract integrity - lesion load (predictive factor).
Baseline
Interhemispheric connectivity of motor cortices assessed using resting-state functional magnetic resonance imaging (rs-fMRI).
時間枠:Baseline
rs-fMRI interhemispheric functional connectivity in the primary motor cortex (predictive factor).
Baseline
Motor cortex mapping and motor representation assessed using neuronavigated transcranial magnetic stimulation (nTMS).
時間枠:Baseline
nTMS motor mapping (predictive factor).
Baseline
Interhemispheric connectivity of motor cortices assessed using resting-state functional electroencephalography (rsEEG).
時間枠:Baseline
rsEEG interhemispheric functional connectivity in the primary motor cortex (predictive factor).
Baseline
Change in upper-extremity Fugl-Meyer assessment (UE-FM) from baseline to the early post-intervention.
時間枠:From baseline to early (within 7 days) post-intervention
Change in UE-FM. UE-FM is a scale that measures upper limb motor function using a scale that runs from 0 to 66 points, with higher scores reflecting better upper extremity motor function.
From baseline to early (within 7 days) post-intervention
Change in Modified Rankin Scale (mRS) from Baseline to the early post-intervention.
時間枠:From baseline to early (within 7 days) post-intervention
Change in mRS. The mRS scale measures global function using a scale that runs from 0 to 6 points, with lower numbers reflecting better global function.
From baseline to early (within 7 days) post-intervention
Change in interhemispheric connectivity of motor cortices assessed using resting-state functional electroencephalography (rsEEG).
時間枠:From baseline to early (within 7 days) post-intervention
Change in rsEEG interhemispheric functional connectivity in the primary motor cortex.
From baseline to early (within 7 days) post-intervention
Change in interhemispheric connectivity of motor cortices assessed using resting-state functional electroencephalography (rsEEG).
時間枠:From baseline to 1-month post-intervention
Change in rsEEG interhemispheric functional connectivity in the primary motor cortex.
From baseline to 1-month post-intervention
Change in motor cortex mapping and motor representation assessed using neuronavigated transcranial magnetic stimulation (nTMS) from baseline to early post-intervention.
時間枠:From baseline to early (within 7 days) post-intervention
nTMS motor mapping (predictive factor).
From baseline to early (within 7 days) post-intervention
Change in motor cortex mapping and motor representation assessed using neuronavigated transcranial magnetic stimulation (nTMS) from baseline to 1 month post-intervention.
時間枠:From baseline to 1 month post-intervention
nTMS motor mapping (predictive factor).
From baseline to 1 month post-intervention

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月12日

一次修了 (推定)

2027年9月15日

研究の完了 (推定)

2028年2月29日

試験登録日

最初に提出

2026年5月24日

QC基準を満たした最初の提出物

2026年6月9日

最初の投稿 (実際)

2026年6月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月12日

QC基準を満たした最後の更新が送信されました

2026年6月9日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Non-PHI data will be shared with appropriate parties after the study is completed and published.

IPD 共有時間枠

Anytime after July, 2028.

IPD 共有アクセス基準

Appropriate parties with appropriate intention for use of the data, starting 07/01/2028, with access to PHI-free data.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

Usual Careの臨床試験

購読する